Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to 13.74%.

  • Organogenesis Holdings' EBIT Margin rose 83200.0% to 13.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.8%, marking a year-over-year increase of 10100.0%. This contributed to the annual value of 0.27% for FY2024, which is 31600.0% down from last year.
  • Latest data reveals that Organogenesis Holdings reported EBIT Margin of 13.74% as of Q3 2025, which was up 83200.0% from 12.45% recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBIT Margin registered a high of 19.15% during Q2 2021, and its lowest value of 30.85% during Q1 2025.
  • For the 5-year period, Organogenesis Holdings' EBIT Margin averaged around 3.18%, with its median value being 7.42% (2023).
  • Per our database at Business Quant, Organogenesis Holdings' EBIT Margin soared by 367400bps in 2021 and then crashed by -273500bps in 2025.
  • Organogenesis Holdings' EBIT Margin (Quarter) stood at 15.45% in 2021, then tumbled by -51bps to 7.55% in 2022, then plummeted by -117bps to 1.27% in 2023, then skyrocketed by 734bps to 8.07% in 2024, then skyrocketed by 70bps to 13.74% in 2025.
  • Its EBIT Margin stands at 13.74% for Q3 2025, versus 12.45% for Q2 2025 and 30.85% for Q1 2025.